SELLAS Life Sciences Group, Inc. (SLS): Total Liabilities
$7.47M
As of 2025-12-31
$7.73M
As of 2026-06-30
-22.6%
3-year compound annual growth
-16.2%
5-year compound annual growth
-19.9%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.47M | -25.0% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $9.97M | -29.8% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $14.20M | -11.8% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $16.09M | +171.5% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $5.93M | -67.2% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $18.09M | +72.0% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $10.52M | -9.9% | 2021-03-23, Balance as of period end |
| 2018-12-31 | $11.67M | -62.9% | 2020-03-13, Balance as of period end |
| 2017-12-31 | $31.46M | +175.5% | 2019-03-22, Balance as of period end |
| 2016-12-31 | $11.42M | -83.4% | 2018-04-13, Balance as of period end |
| 2015-12-31 | $68.63M | +58.0% | 2017-03-15, Balance as of period end |
| 2014-12-31 | $43.43M | -47.1% | 2016-04-15, Balance as of period end |
| 2013-12-31 | $82.09M | +201.5% | 2015-03-05, Balance as of period end |
| 2012-12-31 | $27.23M | +30.6% | 2014-03-17, Balance as of period end |
| 2011-12-31 | $20.86M | +313.3% | 2013-03-12, Balance as of period end |
| 2010-12-31 | $5.05M | n/a | 2012-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | 2025-12-31 | $7.47M | -25.0% |
| Adagene Inc. (ADAG) | 2025-12-31 | $26.36M | -32.0% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $128.86M | +21.9% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $50.21M | +12.4% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $14.06M | -45.5% |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $27.81M | -17.2% |
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | $5.70M | +83.8% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $9.91M | -72.7% |
Compare SLS, ADAG, CPIX, NWBO side by side · Screen every company in Pharmaceutical Preparations ↗